<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84077">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02044549</url>
  </required_header>
  <id_info>
    <org_study_id>Carbitocin</org_study_id>
    <nct_id>NCT02044549</nct_id>
  </id_info>
  <brief_title>Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section</brief_title>
  <official_title>Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of
      Postpartum hemorrhage after cesarean section
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double blind randomized study conducted on 450 pregnant subjected randomly either to
      single 100 μg IV dose of carbetocin (150 women) or combination of 5 IU oxytocin and 0.2 mg
      ergometrine (300 women) after fetal extraction and before placental removal.

      Prevention of postpartum haemorrhage (PPH) after cesarean section (CS) had been evaluated by
      measurement of drop of Hemoglobin and hematocrit, incidence of PPH and number of subjects
      needed additional oxytocic
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>prevention of post partum hemorrhage after CS</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants experienced postpartum hemorrhage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects of drugs used</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of subjects experienced Hemodynamic changes (blood pressure , pulse and respiratory rate ) , GIT side effects as nausea , vomiting and metallic taste, Vasomotor effects as flushing, headache , itching</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Postpartum Hemorrhage</condition>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>carbetocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single 100 μg IV dose of carbetocin (150 women)  after fetal extraction and before placental removal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Syntometrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbetocin</intervention_name>
    <description>Oxycontin analogue</description>
    <arm_group_label>carbetocin</arm_group_label>
    <other_name>Pabal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntometrine</intervention_name>
    <description>Uterotonins</description>
    <arm_group_label>Syntometrine</arm_group_label>
    <other_name>Oxytocin methergine combination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants are at 37 - 40 weeks of gestational age

          -  Noncomplicated pregnancy.

        Exclusion Criteria:

          -  Participants with placenta previa

          -  Patients with coagulopathy

          -  preeclamptic women

          -  known sensitivity to oxytocin or methergine were excluded
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Maged, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ass prof kasr aini medical school</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ahmed Maged</name>
      <address>
        <city>Cairo</city>
        <zip>12151</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Maged</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Carbetocin</keyword>
  <keyword>syntometrine</keyword>
  <keyword>postpartum hemorrhage</keyword>
  <keyword>cesarean section</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
    <mesh_term>Syntometrine</mesh_term>
    <mesh_term>Ergonovine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
